Aktiesnakken — November 2009
-
kun 38 mill dkk effekt i cash på 2009
-
nu egfr
-
we remain highly optimistic
-
hun sagde takeover!!!
-
hun skulle sige stakeholder!
-
ELLER også var det bare mig
-
hun vil godt levere shareholdervalue - jo tak
-
3 spørgsmål fra Piper
-
Er der kontrakt med Lonza for kommerciel produktion af EGFR
-
scaleup work for egfr er completed
-
david eatwell nu. annualized savings 300 mill. 240 cash impact.
-
broadly speaking så kan man trække 300 mill ud, men dog med 1q 2010 der screwer lidt med folk der stadig er tilbage
-
our work with arzerra is winding down
-
kan data være dårlige for egfr...eller ikke så stort som planlagt - kun 3 måneder inden egfr
-
æv dag....
-
var det et spørgsmål aka?
-
ja
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind